TY - JOUR
T1 - Intravenous oxpentifylline and the painful crisis of sickle cell disease
AU - De Ceulaer, K.
AU - Serjeant, G. R.
AU - Nagel, R. L.
AU - Billett, H. H.
AU - Christakis, J.
AU - Loukopoulos, D.
AU - Bellingham, A. J.
AU - Lucas, G. S.
AU - Stuart, J.
PY - 1990
Y1 - 1990
N2 - Oxpentifylline, a synthetic xanthine derivative with a rheological action on sickle cells in vitro, has been assessed for the treatment of sickle cell painful crisis in a double-blind, placebo-controlled, multi-centre trial of 62 patients. Oxpentifylline was given as a continuous intravenous infusion for a maximum of 96 hours. No statistically significant difference between the placebo and treatment groups was found for the clinical end-points of resolution of local tenderness, restoration of local movement, overall mobility, sleep disturbance, and complete resolution of symptoms.
AB - Oxpentifylline, a synthetic xanthine derivative with a rheological action on sickle cells in vitro, has been assessed for the treatment of sickle cell painful crisis in a double-blind, placebo-controlled, multi-centre trial of 62 patients. Oxpentifylline was given as a continuous intravenous infusion for a maximum of 96 hours. No statistically significant difference between the placebo and treatment groups was found for the clinical end-points of resolution of local tenderness, restoration of local movement, overall mobility, sleep disturbance, and complete resolution of symptoms.
UR - http://www.scopus.com/inward/record.url?scp=0025343531&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025343531&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0025343531
SN - 0271-5198
VL - 10
SP - 35
EP - 42
JO - Clinical Hemorheology
JF - Clinical Hemorheology
IS - 1
ER -